Definition and epidemiology
Smallpox is an acute contagious disease caused by variola virus, a member of the Orthopoxvirus genus. Two clinical forms existed: variola major (case-fatality rate 30%) and variola minor or alastrim (case-fatality rate <1%). Smallpox was endemic worldwide for centuries, causing millions of deaths annually.
The global smallpox eradication campaign, led by WHO, began in 1967. The last naturally occurring case was documented in Somalia in 1977. WHO certified global eradication on May 8, 1980. Routine vaccination ceased in most countries by the early 1980s. Variola virus stocks are officially maintained only in two WHO-designated laboratories: CDC (USA) and VECTOR (Russia).
Today, smallpox is relevant primarily as a potential bioterrorism agent. Most individuals born after 1972 have no vaccine-induced immunity. Healthcare workers and laboratory personnel in high-security facilities may receive vaccination. Military personnel and certain first responders may also be vaccinated as part of biodefense preparedness programs.
- Smallpox eradicated 1980; last natural case 1977 Somalia; now bioterrorism threat
- Centrifugal rash (face/extremities > trunk), all lesions same stage—distinguishes from varicella
- Lesions on palms and soles, firm and deep-seated; varicella lesions superficial, multiple stages
- Prodrome: fever, headache, backache before rash; rash appears as fever falls
- Tecovirimat (TPOXX) is first-line antiviral; post-exposure vaccination within 4 days prevents disease
- ACAM2000 vaccine contraindicated in immunocompromised/eczema; JYNNEOS safer, non-replicating
- Airborne and contact precautions; immediate CDC/WHO notification for any suspected case
- Monkeypox mimics smallpox but has prominent lymphadenopathy; PCR distinguishes variola virus
Etiology and risk factors
Smallpox is caused by variola virus, a large double-stranded DNA virus of the Poxviridae family, genus Orthopoxvirus. Variola major caused severe disease; variola minor caused milder illness. The virus is exclusively a human pathogen with no animal reservoir.
Transmission occurred through:
- Respiratory droplets from prolonged face-to-face contact (primary route)
- Direct contact with lesion material or contaminated fomites
- Rarely, airborne transmission in enclosed spaces
Patients were most contagious from onset of rash through scab separation (approximately 3 weeks). Infectivity began with fever and enanthem, before rash appearance.
Historical risk factors included:
- Close contact with infected individuals
- Lack of vaccination
- Living in endemic areas
- Healthcare work without protective measures
Current theoretical risk factors (bioterrorism scenario):
- Lack of vaccination (birth after ~1972)
- Immunocompromised state
- Occupational exposure (laboratory, military, healthcare)
Pathophysiology
After inhalation, variola virus infects respiratory mucosa and migrates to regional lymph nodes. An initial viremia seeds the reticuloendothelial system (liver, spleen, bone marrow). A secondary viremia follows 3-4 days later, with viral seeding of skin and mucous membranes.
The virus infects capillary endothelium and dermal cells, causing the characteristic rash. Lesions begin as macules, evolve to papules, then vesicles and pustules as epithelial cells undergo ballooning degeneration and necrosis. Unlike varicella, smallpox lesions develop synchronously—all lesions are in the same stage at any given time.
Variola major caused extensive viremia and immune dysregulation. Severe forms (hemorrhagic and flat-type smallpox) were associated with inadequate immune responses, leading to uncontrolled viral replication and higher mortality. Hemorrhagic smallpox involved endothelial damage, coagulopathy, and bleeding into skin and mucous membranes.
Recovery depended on robust cell-mediated and humoral immune responses. Survivors developed lifelong immunity. Scarring resulted from dermal destruction during pustule formation.
Clinical features
The incubation period was 10-14 days (range 7-17 days). Patients were asymptomatic during this period.
Prodrome (2-4 days)
- High fever (38.5-40°C)
- Malaise, prostration
- Severe headache, backache
- Vomiting (in 50% of cases)
- Enanthem: small red spots on tongue and oral mucosa
Early rash phase (days 1-4)
Rash appeared as fever began to fall. Distribution was centrifugal—concentrated on face and extremities (including palms and soles), with relative sparing of trunk. Progression:
- Macules: flat, reddish spots
- Papules: raised, firm lesions (days 2-3)
- Vesicles: fluid-filled, tense, deep-seated (days 4-5)
- Pustules: umbilicated, containing thick opaque fluid (days 6-7)
Key distinguishing features:
- All lesions in the same stage of development
- Lesions on palms and soles
- Firm, deep-seated feel
- Patient appears toxic
Late rash phase (days 8-14)
Pustules crusted and scabs formed. Fever recurred during pustulation. Scabs separated over 1-2 weeks, leaving depressed, depigmented scars (pockmarks).
Variant forms
Hemorrhagic smallpox (rare, <3% of cases):
- Severe prostration, bleeding into skin and mucous membranes
- Flat, dusky lesions
- Nearly always fatal
- More common in pregnant women
Flat-type smallpox (5-10% of variola major cases):
- Lesions remained soft, flat, confluent
- Severe toxemia
- High mortality
Modified smallpox: occurred in previously vaccinated individuals; milder course, fewer lesions, lower mortality.
Diagnosis
In the modern era, smallpox diagnosis would be a public health emergency requiring immediate notification of authorities (CDC in the US, equivalent agencies elsewhere).
Clinical diagnosis
Febrile prodrome followed by centrifugal rash with lesions in the same stage is highly suggestive. Clinical criteria (Mack-Rao decision tree) consider:
- Fever onset before rash
- Lesions in same stage
- Centrifugal distribution
- Lesions on palms/soles
- First lesions on oral mucosa/face
- Patient appears toxic
Laboratory confirmation
Specimen collection (only in high-containment laboratory):
- Vesicular or pustular fluid
- Scab material
- Blood samples
Testing methods:
- PCR: real-time PCR for orthopoxvirus and variola-specific sequences (most rapid)
- Electron microscopy: brick-shaped poxvirus particles; cannot distinguish variola from other orthopoxviruses
- Viral culture: only in BSL-4 facilities; not used for initial diagnosis
- Immunofluorescence: orthopoxvirus antigen detection
- Serology: less useful for acute diagnosis
Imaging
No specific imaging required. Chest X-ray may show pneumonia in complicated cases.
Biosafety
All suspected cases require strict airborne and contact precautions. Laboratory testing must occur in high-containment facilities. WHO and national authorities must be notified immediately.
Differential diagnosis
In a bioterrorism scenario, distinguishing smallpox from other vesicular/pustular rashes is critical:
Varicella (chickenpox)
- Most common mimic
- Centripetal distribution (trunk > face/extremities)
- Lesions in multiple stages (macules, papules, vesicles, crusts simultaneously)
- Superficial vesicles, easily unroofed
- Milder systemic symptoms
- Lesions rarely on palms/soles
Monkeypox
- Similar presentation to smallpox
- Prominent lymphadenopathy (helps distinguish)
- Milder disease, lower mortality
- Animal contact history (Africa)
- PCR distinguishes variola from monkeypox virus
Disseminated herpes zoster
- Immunocompromised patients
- Dermatomal distribution initially
- Lesions may be in multiple stages
- History of primary varicella
Disseminated herpes simplex
- Immunocompromised or eczema patients
- Grouped vesicles on erythematous base
- May affect one region predominantly
Generalized vaccinia
- Recent vaccination history
- Rash develops 6-9 days post-vaccination
Drug eruptions (DRESS, SJS/TEN)
- Medication history
- Mucous membrane involvement prominent
- Skin lesions may blister but don't follow smallpox progression
Erythema multiforme/Stevens-Johnson syndrome
- Target lesions
- Prominent mucositis
- Different temporal progression
Impetigo (bullous)
- Superficial, flaccid bullae
- Localized, not generalized
- No systemic prodrome
Rickettsialpox
- Eschar at bite site
- Milder disease
- Papulovesicular rash
PCR testing rapidly distinguishes orthopoxviruses from herpesviruses and other causes.
Management
Smallpox diagnosis would trigger a public health emergency response. Management involves isolation, supportive care, antiviral therapy if available, and containment measures.
Isolation and infection control
- Strict airborne and contact precautions: negative-pressure room, N95 respirators, gowns, gloves
- Patient isolation until all scabs separate
- Healthcare workers should be vaccinated if possible
- Limit personnel exposure
Antiviral therapy
Tecovirimat (ST-246, TPOXX):
- FDA-approved orthopoxvirus treatment (2018)
- Inhibits viral envelope protein p37
- Oral or IV administration
- Should be initiated as early as possible
- Available through Strategic National Stockpile
Brincidofovir:
- Lipid conjugate of cidofovir
- Oral administration
- Alternative if tecovirimat unavailable or resistant
Cidofovir:
- IV only; nephrotoxicity limits use
- Reserved for severe cases if other agents unavailable
Supportive care
- Fluid and electrolyte management
- Pain control
- Wound care to prevent secondary bacterial infection
- Antibiotics if secondary bacterial infection develops
- Management of hemorrhagic complications if present
Vaccination
Post-exposure prophylaxis:
- Vaccinia vaccine (ACAM2000 or JYNNEOS) within 4 days of exposure prevents or attenuates disease
- Within 7 days may reduce severity
- Ring vaccination strategy: vaccinate contacts and contacts of contacts
Vaccines available:
- ACAM2000: live vaccinia virus, replication-competent; effective but has contraindications (immunocompromised, eczema, pregnancy)
- JYNNEOS (Imvamune, Imvanex): live, attenuated, non-replicating vaccinia; safer profile, fewer contraindications
Public health measures
- Immediate notification to CDC/WHO
- Contact tracing and surveillance
- Ring vaccination
- Quarantine of contacts
- Public communication
Special populations
Pregnant women: high risk for hemorrhagic smallpox; antiviral therapy indicated; vaccination with JYNNEOS preferred if post-exposure prophylaxis needed.
Immunocompromised: higher mortality; antiviral therapy essential; JYNNEOS preferred for vaccination.
Children: supportive care and antivirals as for adults; dose adjustments per weight.
Complications and prognosis
Complications
Ocular:
- Keratitis, corneal ulceration
- Blindness (1% of survivors historically)
Bacterial superinfection:
- Cellulitis, sepsis
- Common cause of mortality
Encephalitis:
- Rare (<1%)
- High mortality
Osteomyelitis and arthritis:
- From direct viral invasion
Hemorrhagic complications:
- DIC, multi-organ failure
Scarring:
- Permanent pockmarks on face and body
- Psychological impact
Prognosis
Historically, variola major had 30% case-fatality rate; variola minor had <1%. Mortality was highest in:
- Hemorrhagic and flat-type smallpox (>95%)
- Pregnant women
- Young children and elderly
- Unvaccinated individuals
With modern supportive care and antiviral therapy (tecovirimat), prognosis would likely improve, though exact mortality is unknown since eradication preceded these treatments.
Survivors developed lifelong immunity. Scarring was permanent and often disfiguring.
Long-term sequelae
- Pockmark scarring
- Blindness from corneal scarring
- Limb deformities from osteomyelitis
Modern smallpox would require coordinated international response. Early detection, isolation, vaccination, and antiviral treatment are key to limiting spread.
Smallpox rash progression: My Papa Very Promptly Scabs (Macule → Papule → Vesicle → Pustule → Scab). Remember: SAME stage, SKIN deep lesions (firm), SOLES and palms involved.
Practice questions
1. A 32-year-old man presents with 3 days of high fever, severe headache, and backache. On day 4, he develops a rash starting on his face and forearms that progresses to involve his trunk. Examination shows firm, deep-seated vesicles on an erythematous base, including lesions on his palms. All lesions appear to be in the same stage. He recently returned from a research facility. What is the most appropriate immediate action?
2. A bioterrorism incident is suspected after multiple patients present with fever and rash. A 28-year-old woman has fever, severe backache, and a vesicular rash that began on her face 2 days ago. All vesicles are tense, deep-seated, and in the same stage of development. Palms and soles are involved. Which feature most reliably distinguishes this presentation from varicella?
3. A hospital worker was exposed to a confirmed smallpox patient 48 hours ago. She has no symptoms and was never vaccinated against smallpox. She has a history of atopic dermatitis. What is the most appropriate post-exposure prophylaxis?
Frequently asked questions
What causes smallpox?
Smallpox is caused by variola virus, a large DNA virus of the Orthopoxvirus genus. Variola major caused severe disease with 30% mortality; variola minor (alastrim) caused milder illness with <1% mortality. The virus spreads through respiratory droplets and direct contact. Smallpox was eradicated globally in 1980, so natural infection no longer occurs. Current concern focuses on bioterrorism, as variola virus stocks exist in two WHO-designated laboratories.
What are the first symptoms of smallpox?
Smallpox begins with a prodrome 10-14 days after exposure: high fever (38.5-40°C), severe headache, backache, malaise, and often vomiting. This febrile illness lasts 2-4 days before the rash appears. The rash begins as the fever falls, starting with small red spots in the mouth and on the tongue (enanthem), then spreading to face and extremities. The initial systemic symptoms distinguish smallpox from varicella, which typically has mild prodrome.
How is smallpox diagnosed?
Smallpox diagnosis requires immediate public health notification. Clinical features include febrile prodrome, centrifugal rash (face/extremities predominant), lesions in the same stage, and involvement of palms and soles. Laboratory confirmation uses PCR for variola virus DNA from vesicle fluid or scab material—this is the most rapid and specific test. Electron microscopy shows brick-shaped poxvirus particles. All testing must occur in high-containment laboratories. Varicella is the main differential, distinguished by centripetal rash and lesions in multiple stages.
Is smallpox curable?
Smallpox has no cure, but antiviral therapy and supportive care significantly improve outcomes. Tecovirimat (TPOXX) is FDA-approved for orthopoxvirus infection and inhibits viral replication. Brincidofovir is an alternative. Early initiation of antivirals is critical. Post-exposure vaccination within 4 days can prevent disease; within 7 days it reduces severity. Historically, variola major killed 30% of patients, but modern intensive care and antivirals would likely lower mortality. Survivors develop lifelong immunity but may have permanent scarring.
Smallpox vs chickenpox — what is the difference?
Smallpox and chickenpox differ in rash distribution, lesion staging, and severity. Smallpox has centrifugal distribution (face and extremities, including palms/soles), all lesions in the same stage, deep-seated firm lesions, and severe systemic toxicity. Chickenpox has centripetal distribution (trunk > extremities), lesions in multiple stages simultaneously (macules, vesicles, crusts), superficial easily-ruptured vesicles, and mild systemic symptoms. Smallpox prodrome (fever, backache) precedes rash; chickenpox rash appears with or before fever. PCR rapidly distinguishes variola from varicella-zoster virus.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: B03
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.